MedTrace Logo

Disulfiram Interactions With HIV Medications: Clinical Implications

NCT00878306 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-05-06

No results posted yet for this study

Summary

The purpose of this study is to determine whether disulfiram might be a safe and effective treatment for cocaine and/or alcohol dependence in patients with HIV disease. This research is designed to characterize the presence or absence of significant drug interactions between disulfiram and HIV medications using standard clinical pharmacology techniques as well as monitor any side effects that might occur when these medications are administered together.

Conditions

  • HIV Infections
  • Drug Abuse

Interventions

DRUG

Disulfiram

62.5 mg daily x3 days, then 250 mg daily x3 days

DRUG

Disulfiram + Efavirenz

Efavirenz 600 mg daily x10 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days

DRUG

Disulfiram + Atazanavir

Atazanavir 400 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days

DRUG

Disulfiram + Ritonavir

Ritonavir 200 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days

Sponsors & Collaborators

Principal Investigators

  • Elinore F McCance-Katz, M.D., Ph.D · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00878306 on ClinicalTrials.gov